Regulatory Framework: NDA vs. ANDA

New Drug Application (NDA)

An NDA is a comprehensive application submitted to the FDA by sponsors to formally propose the approval of a new pharmaceutical drug. It contains extensive data on chemistry, manufacturing, controls, preclinical (animal) studies, clinical (human) studies, and proposed labeling.

Abbreviated New Drug Application (ANDA)

An ANDA is submitted to the FDA for the review and potential approval of a generic drug product. It contains data demonstrating bioequivalence to an already approved Reference Listed Drug (RLD), but does not require extensive clinical trials since the safety and efficacy of the drug have already been established by the innovator product.

Key Difference:

NDA requires full reports on safety and effectiveness from original clinical studies, while ANDA relies on the FDA's previous finding of safety and effectiveness for the reference drug, focusing primarily on demonstrating bioequivalence.

What is a Tablet?

Tablets are solid pharmaceutical dosage forms containing drug substances prepared either by compression or molding methods. Although tablets can be manufactured in a wide range of shapes, official tablets are typically defined as circular with either flat or convex faces.

Essential Qualities of a Good Tablet:

  • Accurate and uniform in weight
  • Uniform distribution of drug throughout the tablet
  • Reasonable size and shape for easy administration
  • Appropriate hardness - not too hard to prevent disintegration, not too soft to cause handling problems
  • Attractive appearance without manufacturing defects (cracking, capping, discoloration)
  • Readily disintegrates after administration

Advantages of Tablets

  1. Economical manufacturing: Large scale production is feasible compared to other dosage forms, achieving economy of scale.
  2. Dose accuracy: As a solid unit dosage form, tablets maintain precise dosing.
  3. Tailored release profiles: Modified release tablets can be designed for specific therapeutic needs.
  4. Longer shelf life: Lower moisture content contributes to longer expiry periods and minimal microbial contamination.
  5. Less stringent manufacturing conditions: Since tablets are non-sterile, they don't require aseptic processing environments.
  6. Easy packaging and handling: Can be packaged in blisters, strips, or bottles with minimal difficulty.
  7. Product identification: Variety of shapes, colors, and markings facilitate easy identification.
  8. Transportation: Easy to transport in bulk; patients can carry emergency supplies conveniently.
  9. Organoleptic improvement: Coating can mask unpleasant taste, odor, or appearance.
  10. Versatility: Various types available (buccal, floating, colon-targeting, effervescent, dispersible, soluble, chewable).
  11. Self-administration: Unlike parenteral forms, tablets don't require healthcare professionals for administration.
  12. Tamper-resistant: More difficult to tamper with compared to capsules.

Disadvantages of Tablets

  1. Absorption limitations: Drugs not absorbed or extensively degraded in the GI tract cannot be formulated as tablets.
  2. High-dose API challenges: Difficult to convert a high dose, poorly compressible API into a tablet of suitable size.
  3. Formulation challenges: Drugs with poor wettability or slow dissolution are difficult to formulate into effective tablets.
  4. Slower onset: Compared to parenterals, liquid orals, and capsules, tablets generally have a slower onset of action.
  5. Liquid drug limitations: Very limited capacity to incorporate liquid drugs (e.g., Vitamin E, Simethicone) into tablets.
  6. Swallowing difficulties: Problematic for pediatric, geriatric, and terminally ill patients.
  7. Radiotherapy patients: Patients undergoing radiotherapy often have difficulty swallowing tablets.

Generic vs. Brand Drugs

Reference Listed Drug (RLD)

An RLD is an approved drug product to which new generic versions are compared to show bioequivalence. Generally, the innovator pharmaceutical product (first authorized for marketing based on documentation of quality, safety and efficacy) serves as the RLD.

Generic Drug (US FDA Definition)

A generic drug is identical, or bioequivalent to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.

Basic Requirements for Generic Drugs:

  • Contain the same Active Pharmaceutical Ingredient (API) as the innovator drug (inactive ingredients may vary)
  • Be identical in strength, dosage form, and route of administration to the RLD
  • Have the same use indications as the RLD
  • Be bioequivalent to the RLD
  • Meet the same batch requirements for identity, strength, purity, and quality
Aspect Brand Name Drug Generic Drug
Development Requires extensive clinical trials Relies on brand drug's safety/efficacy data
Cost Higher (R&D costs recovered) Lower (no R&D costs)
Approval Process NDA (New Drug Application) ANDA (Abbreviated NDA)
Excipients Proprietary formulation May differ (inactive ingredients)
Bioequivalence N/A (reference standard) Must demonstrate bioequivalence to RLD

Goal of Formulation Design

  • Stability: To design a stable formulation with acceptable shelf-life
  • Bioavailability: The formulation should be biopharmaceutically effective or bioequivalent to the RLD
  • Patient-friendly: Should be user-friendly to patients and meet minimal elegance criteria
  • Manufacturability: The manufacturing process should be consistent, reproducible, and hiccup-free
  • Cost-effectiveness: The formulation should be economically viable to produce

Systematic Approach to Tablet Design

  1. Pre-formulation Studies: Practical use of pre-formulation data including solid-state properties, solubility analysis, dissolution, stability analysis, and permeability studies.
  2. Excipient Selection: Understanding commonly used tablet excipients with particular emphasis on their advantages and limitations.
  3. Formulation Approaches: Applying general tablet formulation approaches based on API characteristics.
  4. Prototype Development: Developing 2-3 prototype formulations using different techniques (wet granulation, direct compression, dry granulation).
  5. Stability Assessment: Placing prototypes on stability studies and evaluating both physical and chemical stability.
  6. Formulation Evaluation: Assessing API load, excipient ratios, flow properties, hardness, particle size, friability, and dissolution profile.
  7. Process Optimization: Optimizing manufacturing process parameters for consistency and quality.
  8. Process Validation: Validating the manufacturing process to ensure reproducible quality.

Key Consideration:

Prototype formulation development should include API-excipient compatibility studies and evaluation of pH dependency of release rate to ensure robust formulation design.

Critical Pre-formulation Parameters

Solid State Properties:

  • Physical form of drug (amorphous or crystalline)
  • Polymorphism - different crystalline forms of the same compound

Solubility Analysis:

  • Ionization constant (pKa)
  • Partition coefficient (log P)
  • Solubilization techniques
  • Thermal effects on solubility
  • Common ion effect

Dissolution Studies:

Critical for establishing bioavailability and bioequivalence.

Stability Analysis:

  • Solid-state stability studies
  • Solution-state stability studies
  • Drug-excipient compatibility studies

Permeability Studies:

Evaluating API absorption potential across biological membranes.

Particle Properties:

  • Size and shape distribution
  • Powder flow properties
  • Bulk density
  • Compaction behavior

Important: These pre-formulation studies are specific to drug molecules and depend on the chemical structure of the API. They are carried out on the intended dosage form (e.g., tablets and capsules).